Evidence map›Paper›PMID 38962422›Full record

ArticleNagoya journal of medical science2024

Clonal evolution process from essential thrombocythemia to acute myeloid leukemia in the original patient from whom the

Yoko Ushijima, Yuichi Ishikawa, Takahiro Nishiyama, Naomi Kawashima, Takashi Kanamori, Masashi Sanada, Hitoshi Kiyoi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoko UshijimaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuichi IshikawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takahiro NishiyamaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naomi KawashimaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi KanamoriClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Masashi SanadaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported the Marimo cell line, which was established from the bone marrow cells of a patient with essential thrombocythemia (ET) at the last stage after transformation to acute myeloid leukemia (AML). This cell line is widely used for the biological analysis of ET because it harbors

Indexed as

CalreticulinClonal EvolutionLeukemia, Myeloid, AcuteMutationReceptors, ThrombopoietinThrombocythemia, EssentialAgedCell Line, TumorDisease ProgressionFemaleGTP PhosphohydrolasesHumansJanus Kinase 2MaleMembrane ProteinsMiddle AgedCalreticulinCALR protein, humanGTP PhosphohydrolasesJAK2 protein, humanJanus Kinase 2Membrane ProteinsMPL protein, humanNRAS protein, humanReceptors, ThrombopoietinTP53 protein, humanTumor Suppressor Protein p53CALRclonal evolutionessential thrombocythemiaMarimo cell linetransformation

Identifiers

PMID38962422
PMCPMC11219235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.